Endocrine Testing Market Overview 2023 to 2033 | By bioMerieux SA, DiaSorin S.p.A, AB Sciex, Ortho Clinical Diagnostics

The global Endocrine Testing Market size is presently worth US$ 2536.7 million and is predicted to develop at an 8.5% CAGR over the forecast period. Diabetes cases are expected to grow, resulting in a market value of US$ 5735 million by 2032.

Endocrine issues have become more common in the last five years, along with advances in diagnostic methods. Sedentary lifestyles, poor diets, and alcohol consumption are just a few of the important factors expected to drive market growth in the coming years.

For Details on Vendors and Their Offerings – Request A Sample Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-15878

To address the growing prevalence of health disorders as the world’s population ages, effective disease management solutions are required. As a result, there will be a greater demand for Endocrine Testing methodology and solutions, resulting in a large increase in Endocrine Testing demand. Meanwhile, the worldwide directed energy weapons industry is benefiting from increased non-lethal weapon demand.

North America, Europe, and East Asia are likely to be at the forefront of the Endocrine Testing market during the next five years and will maintain their dominance throughout the assessment period, according to the report.

Key Takeaways from the Market Study

• According to the analysis, the Endocrine Testing market would be worth $2536.7 million by 2023.
• The Endocrine Testing industry is expected to grow at an 8.5% CAGR between 2023 and 2033.
• By 2033, Endocrine Testing is expected to be worth $5735 million.
• According to Technology, the follicle-stimulating hormone (FSH) category has a 25% market share and will continue to do so for the foreseeable future.
• By 2033, the North American Endocrine Testing market is expected to grow by 47.2%.

“High prevalence of diabetes, increased spending on research and development, and technological advancements in Endocrine Testing equipment are likely to transform the Endocrine Testing market in the coming years,” comments an analyst at FMI.

Ask More About This Market’s Geographical Distribution Along With a Detailed Analysis of the Top Regions@ https://www.futuremarketinsights.com/ask-question/rep-gb-15878

Competitive Landscape

Abbott Laboratories, AB Sciex, Agilent Technologies Inc., bioMerieux SA, Bio-Rad Laboratories Inc., DiaSorin S.p.A., F. Hoffmann-La Roche Ltd., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated and Ortho Clinical Diagnostics

A number of strategies are being adopted by these firms in an attempt to increase their market share and gain a competitive advantage, including new product launches, facility expansions, mergers, collaborations, partnerships, and acquisitions. For instance,

• In August 2022, Mira Fertility will launch its Mira Fertility Ovum Wand which is intended to monitor the levels of the follicle-stimulating hormone (FSH) in urine. Ovulation is triggered by FSH by stimulating the growth of follicles. This product is listed as an over-the-counter tool by the US Food and Drug Administration (FDA), and it is scheduled to launch in October. It can detect lab-accurate FSH levels, helping identify and predict menopause, assess fertility, and predict ovulation.
• In May 2022, Berlin-based Inne.io startup announced an additional €9.3 million funding round led by DSM Venturing. Calm Storm Ventures and Borski Fund also participated, along with prominent angel investors Taavet Hinrikus (Wise), Fiona Pathiraja, and Rolf Schromgens (Trivago). With over 100,000 points of hormone data collected, Inne has assisted thousands of women in Switzerland, Germany, Austria, and the UK to track their progesterone levels through its mini lab and medical device registration in 2019.

More Valuable Insights Available

FMI, in its new offering, presents an unbiased analysis of the Endocrine Testing market, presenting historical demand data (2018 to 2022) and forecast statistics for the period of 2023 to 2033.

Buy Now to Gain Access to Detailed Information About Each Segment and Identify Key Trends, Drivers, and Challenges in the Market@ https://www.futuremarketinsights.com/checkout/15878

Key Segments Covered in the Endocrine Testing Market Industry Survey

Endocrine Testing Market by Test Type:

• Estradiol (E2) Test in Endocrine Testing
• Human Chorionic Gonadotropin (hCG) Hormone Test in Endocrine Testing
• Follicle Stimulating Hormone (FSH) Test in Endocrine Testing
• Luteinizing Hormone (LH) Test in Endocrine Testing
• Progesterone Test in Endocrine Testing
• Testosterone Test in Endocrine Testing
• Thyroid Stimulating Hormone (TSH) Test in Endocrine Testing
• Dehydroepiandrosterone Sulfate (DHEAS) Test in Endocrine Testing
• Prolactin Test in Endocrine Testing
• Insulin Test in Endocrine Testing
• Cortisol Test in Endocrine Testing
• Others Endocrine Testing

Endocrine Testing Market by Technology:

• Mass Spectroscopy Endocrine Testing
• Chromatography Endocrine Testing
• Immunoassay Endocrine Testing
• Nucleic Acid Based Endocrine Testing

Endocrine Testing Market by End-user:

• Endocrine Testing at Hospitals
• Endocrine Testing at Ambulatory Care Centers
• Endocrine Testing at Commercial Laboratories
• Other Endocrine Testing

About Future Market Insights, Inc.

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn | Twitter | Blogs